Navigation Links
Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
Date:8/23/2007

CAMBRIDGE, Mass., Aug. 23 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced that the company submitted a draft clinical study protocol to the FDA for compassionate use of the investigational product Hemopure (HBOC-201) in the United States. The proposed open label study would make Hemopure available to patients for the treatment of life threatening or potentially life threatening anemia on a compassionate use basis where blood transfusion is not an option.

The product has been available for compassionate use since December 2006. Under the existing program the company evaluates individual requests from treating physicians for specific patients. If the patient is deemed an appropriate candidate for treatment, the FDA is contacted and a single patient IND is requested. To date the FDA has authorized shipment of Hemopure for 20 patients. Of the treated patients, four were experiencing severe anemia secondary to the management and treatment of leukemia and lymphoma. The balance of the compassionate use cases were for the treatment of blood loss resulting from surgical complications or trauma. The remaining patients who were not treated stabilized at the site by the time the drug was received.

The draft protocol outlines general eligibility criteria that include the following:

-- Severe, life threatening, or potentially life threatening anemia

-- Blood transfusion is not feasible

-- All alternative treatment options have been exhausted

-- Adult male or female - 18 years of age, or child with anemia secondary

to severe burns

The safety, efficacy and pharmacology of Hemopure have been studied in 22 completed clinical trials. An additional four trial
'/>"/>

SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ROSEMONT, Ill. , Aug. 3, 2015 ... ankle problem, and you,re looking for the best possible ... for the best outcome too, and now there,s a ... there. Following steps recommended by the American Orthopaedic ... after surgery can help you avoid complications and heal ...
(Date:8/3/2015)... FRANCISCO , Aug. 3, 2015  Sage Analytics ... of portable laboratory-quality cannabis potency measurement systems, announced its ... Bay Area Cruise Fundraiser. A limited number of tickets ... festivities and help a great cause while enjoying an ... scenic cruise around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... FRANCISCO , August 3, 2015 ... size is expected to reach USD 24.7 billion ... Grand View Research Inc. Growing prevalence of neurological ... physiotherapy equipments market over the forecast period. The ... ultrasound and cryotherapy, advancement in the technologies coupled ...
Breaking Medicine Technology:Patient Guide: How to Prepare for Surgery 2Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5
... Echo Therapeutics, Inc. (OTC Bulletin Board: ... System as a non-invasive, wireless, transdermal continuous glucose monitoring ... delivery, today announced that it has raised approximately $2.5 ... Company,s stock and warrants, and it has received a ...
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... officer, is scheduled to present a company overview at the ... January 13th at 11:30 a.m. PST. (Logo:   ... or the subsequent archived recording, log on to www.rigel.com ...
Cached Medicine Technology:Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 2Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 3Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 4
(Date:8/3/2015)... Ore. (PRWEB) , ... August 03, 2015 , ... They ... Providence St. Vincent Medical Center offers some of the best care in ... M.D., neurosurgeon and neurointerventionalist, achieved the fastest average blood clot removal time in the ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of Appeals ruled in favor of the firm’s client Rebecca Hamsher, deciding that ... Medical Center must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and ...
(Date:8/3/2015)... PA (PRWEB) , ... August 03, 2015 , ... ... Africa , Infectious diseases researchers from the University of Pittsburgh School of Medicine ... rollout of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can ... costs. , Annually, more than 8.6 million adverse drug events are reported ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... Inc.,(Nasdaq: ATRC ), a medical device company ... announced that its minimally invasive platform was,highlighted during ... techniques. On June 18, Dr. Kenneth,Ellenbogen, Vice Chairman ... Pacing at the Medical College of Virginia, chaired ...
... on MRIs with limited side effects, study found , , FRIDAY, ... to treat the "relapse-remitting" form of multiple sclerosis has been ... , Although the drug, laquinimod, is still experimental, having a ... patients. , "By and large, this doesn,t look as strong ...
... PRGO ; TASE) today announced that it ... Drug Administration to manufacture and market,Cetirizine Hydrochloride Syrup ... Consumer Healthcare,s Zyrtec(R) Syrup, 1mg/mL, indicated for the,relief ... Perrigo,s Chairman and CEO Joseph C. Papa stated, ...
... no added benefit , , THURSDAY, June 19 (HealthDay News) ... risk of HIV-1 infection in people who have sex ... finds. , Previous research has shown that herpes simplex ... of genital herpes -- increases the risk for HIV-1 ...
... Bills Delay and Fix Competitive Bidding System for ... Pete Stark,(D-CA), chair of the House Ways & ... DMEPOS Competitive Acquisition Reform,Act of 2008. Sens. Max ... member of the Senate Finance Committee, have introduced ...
... The results of a major international clinical trial coordinated ... the New England Journal of Medicine . The ... a prospective, multicentre project involving patients with heart failure ... of death in the population and associated atrial fibrillation ...
Cached Medicine News:Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 2Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 3Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 4Health News:Experimental Drug Fights Multiple Sclerosis Activity 2Health News:Experimental Drug Fights Multiple Sclerosis Activity 3Health News:Perrigo Announces Approval for Rx Cetirizine Syrup 2Health News:Herpes Suppression May Not Prevent HIV Infection 2Health News:NCPA Statement Endorsing H.R. 6252 and S.3144 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 3
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
The revision knee system for severe joint deterioration with insufficient ligament support....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
The GENESIS II* Total Knee System will define the state of knee implants....
Medicine Products: